ClinicalTrials.gg
CompletedNCT01519960Updated Nov 18, 2022Results posted

A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

A Phase 3 interventional study of peginterferon alfa-2a [Pegasys] and peginterferon alfa-2a [Pegasys] in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 39 sites in 12 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-11-18.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
20th of 59
165 · median 114
Started
2012
with 3 others
Phase 3
11 of 59
none open now
Registered
27th of 59
by date
Lead sponsor
22 of 59
Hoffmann-La Roche

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 20th largest by enrollment, is one of 4 that started in 2012, is one of 11 in phase 3, and was the 27th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This parallel group, open label study will evaluate the safety and efficacy of Pegasys (peginterferon alfa-2a) versus untreated control in children (age 3 years to \<18 years at baseline) with HBeAg positive chronic hepatitis B. Children without advanced fibrosis and without cirrhosis will be randomized 2:1 to treatment Group A, receiving Pegasys 45-180 mcg subcutaneously weekly for 48 weeks, or to the untreated control Group B. Children with advanced fibrosis will be assigned to treatment group C and receive 48 weeks of treatment with Pegasys. Children in the untreated control Group B who have not experienced seroconversion 48 weeks after randomization may enter the Switch Arm to receive 48 weeks of Pegasys treatment. This offer will be available for 1 year following 48 weeks from randomization. Anticipated time on study treatment is 48 weeks. All subjects will be followed up for 5 years after the end of treatment (A,C,Switch)/principal observation (B) period.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients, 3 years to \<18 years of age at baseline
  • Positive for more than 6 months
  • Positive HBeAg and detectable HBV DNA at screening
  • A liver obtained within the past 2 years prior to baseline (and more than 6 months after the end of previous therapy for hepatitis B) to confirm the presence of advanced fibrosis or exclude cirrhosis
  • Compensated liver disease ( Class A)
  • Elevated serum alanine transferase ()
  • Normal thyroid gland function at screening

Exclusion criteria

Exclusion Criteria:

  • Subjects with cirrhosis
  • Subjects must not have received drugs or licensed treatments with anti- activity within 6 months of baseline. Subjects who are expected to need systemic antiviral therapy other than that provided by the study at any time during their participation in the study are also excluded
  • Known to peginterferon
  • Positive test results at screening for hepatitis A, , hepatitis D or infection
  • History or evidence of medical condition associated with chronic liver disease other than chronic hepatitis B
  • History or evidence of bleeding from esophageal varices
  • Decompensated liver disease (e.g. ascites, Class B or C)
  • History of immunologically mediated disease
  • Pregnant or lactating females
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    A Pegasys

    Drug: peginterferon alfa-2a [Pegasys]

  • No intervention
    B Untreated Control
  • Experimental
    C Fibrosis non-randomized

    Drug: peginterferon alfa-2a [Pegasys]

  • Experimental
    Switch

    Drug: peginterferon alfa-2a [Pegasys]

Interventions

  • Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48

  • Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HBeAg Seroconversion at 24 Weeks After End of Treatment (EOT)/POP in Groups A and B

    HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.

    Time frame: FU Week 24 (up to 72 weeks overall)

Secondary outcomes

  1. Percentage of Participants With Loss of HBeAg at 24 Weeks After EOT/POP in Groups A and B

    The percentage of participants with loss of HBeAg at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  2. Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion at 24 Weeks After EOT/POP in Groups A and B

    HBsAg seroconversion was defined as loss of HBsAg and the presence of hepatitis B surface antibody (anti-HBs). The percentage of participants with HBsAg seroconversion at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  3. Percentage of Participants With Normal ALT at 24 Weeks After EOT/POP in Groups A and B

    Normal ALT was defined as ALT less than or equal to (≤) ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  4. Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After EOT/POP in Groups A and B

    HBV DNA was quantified using polymerase chain reaction (PCR) by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  5. Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B

    HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  6. Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  7. Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  8. Percentage of Participants With HBeAg Seroconversion at EOT/POP in Groups A and B

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: Week 48

  9. Percentage of Participants With Loss of HBeAg at EOT/POP in Groups A and B

    The percentage of participants with loss of HBeAg at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: Week 48

  10. Percentage of Participants With HBsAg Seroconversion at EOT/POP in Groups A and B

    HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: Week 48

  11. Percentage of Participants With Loss of HBsAg at EOT/POP in Groups A and B

    The percentage of participants with loss of HBsAg at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: Week 48

  12. Percentage of Participants With Normal ALT at EOT/POP in Groups A and B

    Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: Week 48

  13. Percentage of Participants With HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B

    HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: Week 48

  14. Percentage of Participants With HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B

    HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: Week 48

  15. Percentage of Participants With HBV DNA Undetectable at EOT/POP in Groups A and B

    HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: Week 48

  16. Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: Week 48

  17. Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: Week 48

  18. Quantitative Serum ALT Level in Groups A and B

    Quantitative ALT at each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). ITT Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  19. Quantitative HBV DNA Level in Groups A and B

    Quantitative HBV DNA at each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Baseline; Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  20. Change From Baseline in Quantitative HBV DNA Level in Groups A and B

    The change in quantitative HBV DNA from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  21. Percentage of Participants With Loss of HBeAg at 24 Weeks After EOT in Group C

    The percentage of participants with loss of HBeAg at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population: All participants who received at least one dose of study drug (if assigned) and had at least one post-baseline safety assessment.

    Time frame: FU Week 24 (up to 72 weeks overall)

  22. Percentage of Participants With HBsAg Seroconversion at 24 Weeks After EOT in Group C

    HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  23. Percentage of Participants With Loss of HBsAg at 24 Weeks After EOT in Group C

    The percentage of participants with loss of HBsAg at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population

    Time frame: FU Week 24 (up to 72 weeks overall)

  24. Percentage of Participants With Normal ALT at 24 Weeks After EOT in Group C

    Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  25. Percentage of Participants With HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C

    HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  26. Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C

    HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  27. Percentage of Participants With HBV DNA Undetectable at 24 Weeks After EOT in Group C

    HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  28. Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  29. Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  30. Percentage of Participants With HBeAg Seroconversion at EOT in Group C

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: Week 48

  31. Percentage of Participants With Loss of HBeAg at EOT in Group C

    The percentage of participants with loss of HBeAg at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: Week 48

  32. Percentage of Participants With HBsAg Seroconversion at EOT in Group C

    HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: Week 48

  33. Percentage of Participants With Loss of HBsAg at EOT in Group C

    The percentage of participants with loss of HBsAg at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: Week 48

  34. Percentage of Participants With Normal ALT at EOT in Group C

    Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: Week 48

  35. Percentage of Participants With HBV DNA <20,000 IU/mL at EOT in Group C

    HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: Week 48

  36. Percentage of Participants With HBV DNA <2,000 IU/mL at EOT in Group C

    HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: Week 48

  37. Percentage of Participants With HBV DNA Undetectable at EOT in Group C

    HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: Week 48

  38. Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT in Group C

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: Week 48

  39. Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT in Group C

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: Week 48

  40. Quantitative Serum ALT Level in Group C

    Quantitative ALT at each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  41. Quantitative HBV DNA Level in Group C

    Quantitative HBV DNA at each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Baseline; Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  42. Change From Baseline in Quantitative HBV DNA Level in Group C

    The change in quantitative HBV DNA from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  43. Estimated Area Under the Concentration-Time Curve (AUC) by BSA Category

    AUC was estimated using population pharmacokinetic (PK) modeling. The AUC at steady-state was averaged among participants who received PEG-IFN and reported by BSA category. Categories of BSA-based dosing used in the analysis were as follows: 0.54-0.74 m\^2, 65 mcg; 0.75-1.08 m\^2, 90 mcg; 1.09-1.51 m\^2, 135 mcg; \>1.51 m\^2, 180 mcg. The estimated AUC was expressed in hours by nanograms per milliliter (h\*ng/mL). PK Substudy Population: All participants who consented to participate in the PK substudy. "Number of subjects analyzed" reflects the total combined number of participants who provided evaluable data across all BSA categories. The number of participants who provided evaluable data within each BSA category (n) is shown in the table.

    Time frame: Pre-dose (0 hours) at Baseline and Weeks 4, 8, 12, 24; post-dose (24-48, 72-96, 168 hours) during Weeks 1, 24 (up to 24 weeks overall)

  44. Percentage of Participants With >15% Drop in Height Percentile for Age in Groups A and B

    The percentage of participants with \>15% drop in height percentile for age from Baseline to each visit was reported. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Weeks 12, 24, 36, 48; FU Weeks 12, 24 (up to 72 weeks overall)

  45. Percentage of Participants With >15% Drop in Weight Percentile for Age in Groups A and B

    The percentage of participants with \>15% drop in weight percentile for age from Baseline to each visit was reported. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Weeks 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  46. Quantitative HBeAg Level in Groups A and B

    Quantitative HBeAg at each visit was averaged among all participants and expressed in log10 Paul Ehrlich Institute units per milliliter (PEIU/mL). ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)

  47. Quantitative HBsAg Level in Groups A and B

    Quantitative HBsAg at each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)

  48. Quantitative HBeAg Level in Group C

    Quantitative HBeAg at each visit was averaged among all participants and expressed in log10 PEIU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)

  49. Quantitative HBsAg Level in Group C

    Quantitative HBsAg at each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population.

    Time frame: Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)

  50. Change From Baseline in Liver Stiffness Measure (LSM) in Groups A, B, C

    Liver elastography was performed to assess elasticity and extent of hepatic fibrosis. The change in LSM from Baseline to each visit was averaged among all participants in expressed in kilopascals (kPa). Positive changes in LSM values corresponded to an increase in stiffness and hepatic fibrosis. Liver Substudy Population: All participants who consented to participate in the liver elasticity substudy. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Week 48; FU Week 24 (up to 72 weeks overall)

  51. Percentage of Participants With >15% Drop in Height Percentile for Age in Group C

    The percentage of participants with \>15% drop in weight percentile for age from Baseline to each visit was reported. Safety Population.

    Time frame: Weeks 30, 36; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  52. Change From Baseline in Height for Age Z-Score in Groups A and B

    The difference between the population mean and raw scores was calculated as the height for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Baseline; Weeks 12, 24, 36, 48; FU Weeks 12, 24 (up to 72 weeks overall)

  53. Change From Baseline in Weight for Age Z-Score in Groups A and B

    The difference between the population mean and raw scores was calculated as the weight for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations.Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  54. Change From Baseline in Height for Age Z-Score in Group C

    The difference between the population mean and raw scores was calculated as the height for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population.

    Time frame: Baseline; Weeks 12, 24, 36, 48; FU Weeks 12, 24 (up to 72 weeks overall)

  55. Change From Baseline in Weight for Age Z-Score in Group C

    The difference between the population mean and raw scores was calculated as the weight for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  56. Percentage of Participants With HBeAg Seroconversion at 24 Weeks After EOT in Group C

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  57. Change From Baseline in Quantitative Serum ALT Level in Groups A and B

    The change in quantitative ALT from Baseline to each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  58. Change From Baseline in Quantitative HBeAg Level in Groups A and B

    The change in quantitative HBeAg from Baseline to each visit was averaged among all participants and expressed in log10 PEIU/mL. ITT Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)

  59. Change From Baseline in Quantitative HBsAg Level in Groups A and B

    The change in quantitative HBsAg from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)

  60. Change From Baseline in Quantitative Serum ALT Level in Group C

    The change in quantitative ALT from Baseline to each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)

  61. Change From Baseline in Quantitative HBeAg Level in Group C

    The change in quantitative HBeAg from Baseline to each visit was averaged among all participants and expressed in log10 PEIU/mL. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

    Time frame: Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)

  62. Change From Baseline in Quantitative HBsAg Level in Group C

    The change in quantitative HBsAg from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population.

    Time frame: Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)

  63. Percentage of Participants With HBeAg Seroconversion Over Time in Groups A and B

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: Baseline, FU Years: 1, 2, 3, 4, 5

  64. Percentage of Participants With Loss of HBeAg at 24 Weeks After the End of Switch Treatment Period: Switch Group

    The percentage of participants with loss of HBeAg at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  65. Percentage of Participants With HBsAg Seroconversion at 24 Weeks After the End of Switch Treatment Period: Switch Group

    HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.

    Time frame: FU Week 24 (up to 72 weeks overall)

  66. Percentage of Participants With Loss of HBsAg at 24 Weeks After the End of Switch Treatment Period: Switch Group

    HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.

    Time frame: FU Week 24 (up to 72 weeks overall)

  67. Percentage of Participants With Normal ALT at 24 Weeks After the End of Switch Treatment Period: Switch Group

    Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  68. Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After the End of Switch Treatment Period: Switch Group

    HBV DNA was quantified using polymerase chain reaction (PCR) by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  69. Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group

    HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  70. Percentage of Participants With HBV DNA Undetectable at 24 Weeks After the End of Switch Treatment Period: Switch Group

    HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  71. Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

  72. Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group

    HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

    Time frame: FU Week 24 (up to 72 weeks overall)

07

Results

Posted Aug 17, 2016

Participant flow

Participant flow — Overall Study
MilestoneGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced FibrosisGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Started1015010
Completed week 48994710
Completed follow-up (fu) week 12992610
Completed fu week 24991510
Completed fu 5 year75285
Switch group0330
Completed75285
Not completed26225
Withdrew: Withdrawal from the study26225

Outcome measures

PrimaryPercentage of Participants With HBeAg Seroconversion at 24 Weeks After End of Treatment (EOT)/POP in Groups A and B

HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Seroconversion at 24 Weeks After End of Treatment (EOT)/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With HBeAg Seroconversion at 24 Weeks After End of Treatment (EOT)/POP in Groups A and B25.7 ± 17.566 ± 1.25
Statistical analysis
  • Group A: PEG-IFN Monotherapy Without Advanced Fibrosis vs Group B: Untreated Control Without Advanced Fibrosis · Cochran-Mantel-Haenszel · p = = 0.0043 · Odds ratio (or): 5.43 · 95% CI 1.54 to 19.2
  • Group A: PEG-IFN Monotherapy Without Advanced Fibrosis vs Group B: Untreated Control Without Advanced Fibrosis · Breslow-Day · p = = 0.3732
SecondaryPercentage of Participants With Loss of HBeAg at 24 Weeks After EOT/POP in Groups A and B

The percentage of participants with loss of HBeAg at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Loss of HBeAg at 24 Weeks After EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With Loss of HBeAg at 24 Weeks After EOT/POP in Groups A and B25.7 ± 17.566 ± 1.25
SecondaryPercentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion at 24 Weeks After EOT/POP in Groups A and B

HBsAg seroconversion was defined as loss of HBsAg and the presence of hepatitis B surface antibody (anti-HBs). The percentage of participants with HBsAg seroconversion at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion at 24 Weeks After EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion at 24 Weeks After EOT/POP in Groups A and B7.9 ± 3.480 ± 0
SecondaryPercentage of Participants With Normal ALT at 24 Weeks After EOT/POP in Groups A and B

Normal ALT was defined as ALT less than or equal to (≤) ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at 24 Weeks After EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With Normal ALT at 24 Weeks After EOT/POP in Groups A and B51.5 ± 41.3312 ± 4.53
SecondaryPercentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After EOT/POP in Groups A and B

HBV DNA was quantified using polymerase chain reaction (PCR) by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After EOT/POP in Groups A and B33.7 ± 24.564 ± 0.49
SecondaryPercentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B

HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B28.7 ± 20.152 ± 0.05
SecondaryPercentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B22.8 ± 15.024 ± 0.49
SecondaryPercentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B19.8 ± 12.542 ± 0.05
SecondaryPercentage of Participants With HBeAg Seroconversion at EOT/POP in Groups A and B

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Seroconversion at EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With HBeAg Seroconversion at EOT/POP in Groups A and B7.9 ± 3.486 ± 1.25
SecondaryPercentage of Participants With Loss of HBeAg at EOT/POP in Groups A and B

The percentage of participants with loss of HBeAg at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Loss of HBeAg at EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With Loss of HBeAg at EOT/POP in Groups A and B8.9 ± 4.166 ± 1.25
SecondaryPercentage of Participants With HBsAg Seroconversion at EOT/POP in Groups A and B

HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With HBsAg Seroconversion at EOT/POP in Groups A and B6.9 ± 2.830 ± 0
SecondaryPercentage of Participants With Loss of HBsAg at EOT/POP in Groups A and B

The percentage of participants with loss of HBsAg at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Loss of HBsAg at EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With Loss of HBsAg at EOT/POP in Groups A and B10.9 ± 5.560 ± 0
SecondaryPercentage of Participants With Normal ALT at EOT/POP in Groups A and B

Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With Normal ALT at EOT/POP in Groups A and B18.8 ± 11.7222 ± 11.53
SecondaryPercentage of Participants With HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B

HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B36.6 ± 27.2712 ± 4.53
SecondaryPercentage of Participants With HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B

HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B30.7 ± 21.92 ± 0.05
SecondaryPercentage of Participants With HBV DNA Undetectable at EOT/POP in Groups A and B

HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA Undetectable at EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With HBV DNA Undetectable at EOT/POP in Groups A and B18.8 ± 11.720 ± 0
SecondaryPercentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B6.9 ± 2.836 ± 1.25
SecondaryPercentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B6.9 ± 2.830 ± 0
SecondaryQuantitative Serum ALT Level in Groups A and B

Quantitative ALT at each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). ITT Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Mean · factor of ULN
Quantitative Serum ALT Level in Groups A and B
factor of ULNGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Baseline2.779 ± 2.4832.878 ± 1.997
Week 13.427 ± 2.687—
Week 22.846 ± 1.885—
Week 43.343 ± 2.455—
Week 83.262 ± 2.797—
Week 123.189 ± 3.06—
Week 183.036 ± 2.389—
Week 242.753 ± 2.7252.401 ± 2.638
Week 302.587 ± 2.128—
Week 362.45 ± 1.8562.341 ± 2.204
Week 422.316 ± 1.429—
Week 482.122 ± 1.3891.954 ± 1.371
FU Week 41.303 ± 1.74—
FU Week 122.064 ± 2.027—
FU Week 241.477 ± 1.6251.7 ± 1.385
SecondaryQuantitative HBV DNA Level in Groups A and B

Quantitative HBV DNA at each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Baseline; Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Mean · log10 IU/mL
Quantitative HBV DNA Level in Groups A and B
log10 IU/mLGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Baseline8.094 ± 0.9868.056 ± 0.987
Week 126.49 ± 2.0097.909 ± 1.267
Week 245.966 ± 2.3987.857 ± 1.327
Week 365.575 ± 2.5137.685 ± 1.608
Week 485.224 ± 2.7017.551 ± 1.761
FU Week 45.739 ± 2.935—
FU Week 125.914 ± 3.0657.214 ± 2.46
FU Week 245.707 ± 3.1137.2 ± 2.506
SecondaryChange From Baseline in Quantitative HBV DNA Level in Groups A and B

The change in quantitative HBV DNA from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Mean · log10 IU/mL
Change From Baseline in Quantitative HBV DNA Level in Groups A and B
log10 IU/mLGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Week 12-1.588 ± 1.625-0.156 ± 1.093
Week 24-2.112 ± 1.996-0.168 ± 1.214
Week 36-2.525 ± 2.148-0.359 ± 1.411
Week 48-2.877 ± 2.374-0.493 ± 1.518
FU Week 4-2.34 ± 2.582—
FU Week 12-2.164 ± 2.737-0.86 ± 2.163
FU Week 24-2.381 ± 2.778-0.587 ± 2.259
SecondaryPercentage of Participants With Loss of HBeAg at 24 Weeks After EOT in Group C

The percentage of participants with loss of HBeAg at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population: All participants who received at least one dose of study drug (if assigned) and had at least one post-baseline safety assessment.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Loss of HBeAg at 24 Weeks After EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With Loss of HBeAg at 24 Weeks After EOT in Group C30 ± 6.67
SecondaryPercentage of Participants With HBsAg Seroconversion at 24 Weeks After EOT in Group C

HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at 24 Weeks After EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With HBsAg Seroconversion at 24 Weeks After EOT in Group C0 ± 0
SecondaryPercentage of Participants With Loss of HBsAg at 24 Weeks After EOT in Group C

The percentage of participants with loss of HBsAg at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Loss of HBsAg at 24 Weeks After EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With Loss of HBsAg at 24 Weeks After EOT in Group C0 ± 0
SecondaryPercentage of Participants With Normal ALT at 24 Weeks After EOT in Group C

Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at 24 Weeks After EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With Normal ALT at 24 Weeks After EOT in Group C70 ± 34.75
SecondaryPercentage of Participants With HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C

HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C70 ± 34.75
SecondaryPercentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C

HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C70 ± 34.75
SecondaryPercentage of Participants With HBV DNA Undetectable at 24 Weeks After EOT in Group C

HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA Undetectable at 24 Weeks After EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With HBV DNA Undetectable at 24 Weeks After EOT in Group C30 ± 6.67
SecondaryPercentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C30 ± 6.67
SecondaryPercentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C30 ± 6.67
SecondaryPercentage of Participants With HBeAg Seroconversion at EOT in Group C

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Seroconversion at EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With HBeAg Seroconversion at EOT in Group C20 ± 2.52
SecondaryPercentage of Participants With Loss of HBeAg at EOT in Group C

The percentage of participants with loss of HBeAg at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Loss of HBeAg at EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With Loss of HBeAg at EOT in Group C20 ± 2.52
SecondaryPercentage of Participants With HBsAg Seroconversion at EOT in Group C

HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With HBsAg Seroconversion at EOT in Group C0 ± 0
SecondaryPercentage of Participants With Loss of HBsAg at EOT in Group C

The percentage of participants with loss of HBsAg at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Loss of HBsAg at EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With Loss of HBsAg at EOT in Group C0 ± 0
SecondaryPercentage of Participants With Normal ALT at EOT in Group C

Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With Normal ALT at EOT in Group C40 ± 12.16
SecondaryPercentage of Participants With HBV DNA <20,000 IU/mL at EOT in Group C

HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA <20,000 IU/mL at EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With HBV DNA <20,000 IU/mL at EOT in Group C40 ± 12.16
SecondaryPercentage of Participants With HBV DNA <2,000 IU/mL at EOT in Group C

HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA <2,000 IU/mL at EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With HBV DNA <2,000 IU/mL at EOT in Group C30 ± 6.67
SecondaryPercentage of Participants With HBV DNA Undetectable at EOT in Group C

HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA Undetectable at EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With HBV DNA Undetectable at EOT in Group C20 ± 2.52
SecondaryPercentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT in Group C

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT in Group C20 ± 2.52
SecondaryPercentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT in Group C

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT in Group C20 ± 2.52
SecondaryQuantitative Serum ALT Level in Group C

Quantitative ALT at each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Mean · factor of ULN
Quantitative Serum ALT Level in Group C
factor of ULNGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Baseline2.804 ± 1.118
Week 13.117 ± 1.322
Week 22.896 ± 1.304
Week 42.444 ± 1.727
Week 82.703 ± 2.035
Week 122.793 ± 1.288
Week 182.215 ± 1.032
Week 241.887 ± 1.095
Week 302.22 ± 1.553
Week 362.172 ± 1.09
Week 421.593 ± 0.516
Week 481.645 ± 1.242
FU Week 41.136 ± 0.506
FU Week 121.521 ± 0.755
FU Week 241.549 ± 1.595
SecondaryQuantitative HBV DNA Level in Group C

Quantitative HBV DNA at each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Baseline; Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Mean · log10 IU/mL
Quantitative HBV DNA Level in Group C
log10 IU/mLGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Baseline7.866 ± 0.977
Week 125.782 ± 1.771
Week 245.599 ± 2.386
Week 365.2 ± 2.451
Week 485.319 ± 2.747
FU Week 44.604 ± 2.442
FU Week 124.252 ± 2.596
FU Week 243.694 ± 3.127
SecondaryChange From Baseline in Quantitative HBV DNA Level in Group C

The change in quantitative HBV DNA from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Mean · log10 IU/mL
Change From Baseline in Quantitative HBV DNA Level in Group C
log10 IU/mLGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Week 12-2.084 ± 1.1
Week 24-2.267 ± 1.595
Week 36-2.529 ± 1.879
Week 48-2.546 ± 2.14
FU Week 4-3.262 ± 2.102
FU Week 12-3.613 ± 2.519
FU Week 24-4.15 ± 2.904
SecondaryEstimated Area Under the Concentration-Time Curve (AUC) by BSA Category

AUC was estimated using population pharmacokinetic (PK) modeling. The AUC at steady-state was averaged among participants who received PEG-IFN and reported by BSA category. Categories of BSA-based dosing used in the analysis were as follows: 0.54-0.74 m\^2, 65 mcg; 0.75-1.08 m\^2, 90 mcg; 1.09-1.51 m\^2, 135 mcg; \>1.51 m\^2, 180 mcg. The estimated AUC was expressed in hours by nanograms per milliliter (h\*ng/mL). PK Substudy Population: All participants who consented to participate in the PK substudy. "Number of subjects analyzed" reflects the total combined number of participants who provided evaluable data across all BSA categories. The number of participants who provided evaluable data within each BSA category (n) is shown in the table.

Time frame:
Pre-dose (0 hours) at Baseline and Weeks 4, 8, 12, 24; post-dose (24-48, 72-96, 168 hours) during Weeks 1, 24 (up to 24 weeks overall)
Reported as:
Mean · h*ng/mL
Estimated Area Under the Concentration-Time Curve (AUC) by BSA Category
h*ng/mLAll Groups Combined
0.54-0.74 m^23320 (633 to 5064)
0.75-1.08 m^24037 (1897 to 6916)
1.09-1.51 m^22765 (1750 to 4392)
>1.51 m^23448 (1914 to 5000)
SecondaryPercentage of Participants With >15% Drop in Height Percentile for Age in Groups A and B

The percentage of participants with \>15% drop in height percentile for age from Baseline to each visit was reported. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Weeks 12, 24, 36, 48; FU Weeks 12, 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With >15% Drop in Height Percentile for Age in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Week 1210
Week 2458.5
Week 3644.2
Week 486.12.1
FU Week 1210.94.2
FU Week 24126.7
SecondaryPercentage of Participants With >15% Drop in Weight Percentile for Age in Groups A and B

The percentage of participants with \>15% drop in weight percentile for age from Baseline to each visit was reported. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Weeks 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With >15% Drop in Weight Percentile for Age in Groups A and B
percentage of participantsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Week 42—
Week 85—
Week 125.12.1
Week 188.1—
Week 24168.5
Week 3013.1—
Week 3611.38.3
Week 4213.1—
Week 4812.58.5
FU Week 48.1—
FU Week 126.920.8
FU Week 241120
SecondaryQuantitative HBeAg Level in Groups A and B

Quantitative HBeAg at each visit was averaged among all participants and expressed in log10 Paul Ehrlich Institute units per milliliter (PEIU/mL). ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Reported as:
Mean · log10 PEIU/mL
Quantitative HBeAg Level in Groups A and B
log10 PEIU/mLGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Baseline2.736 ± 0.5022.568 ± 0.65
Week 122.09 ± 0.8792.391 ± 0.878
Week 241.865 ± 0.9562.36 ± 0.896
Week 361.604 ± 0.9912.272 ± 0.985
Week 481.466 ± 1.0532.124 ± 1.091
FU Week 241.537 ± 1.3342.217 ± 1.395
SecondaryQuantitative HBsAg Level in Groups A and B

Quantitative HBsAg at each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Reported as:
Mean · log10 IU/mL
Quantitative HBsAg Level in Groups A and B
log10 IU/mLGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Baseline4.309 ± 0.6874.383 ± 0.721
Week 123.844 ± 1.1864.299 ± 0.809
Week 243.509 ± 1.5074.336 ± 0.732
Week 363.265 ± 1.6614.272 ± 0.726
Week 483.078 ± 1.7694.215 ± 0.718
FU Week 243.37 ± 1.634.394 ± 0.939
SecondaryQuantitative HBeAg Level in Group C

Quantitative HBeAg at each visit was averaged among all participants and expressed in log10 PEIU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Reported as:
Mean · log10 PEIU/mL
Quantitative HBeAg Level in Group C
log10 PEIU/mLGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Baseline2.344 ± 0.981
Week 121.62 ± 1.288
Week 241.802 ± 1.14
Week 361.561 ± 1.178
Week 481.429 ± 1.259
FU Week 241.442 ± 1.416
SecondaryQuantitative HBsAg Level in Group C

Quantitative HBsAg at each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population.

Time frame:
Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Reported as:
Mean · log10 IU/mL
Quantitative HBsAg Level in Group C
log10 IU/mLGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Baseline4.225 ± 0.518
Week 123.829 ± 0.589
Week 243.515 ± 1.113
Week 363.282 ± 1.263
Week 483.215 ± 1.352
FU Week 243.137 ± 1.463
SecondaryChange From Baseline in Liver Stiffness Measure (LSM) in Groups A, B, C

Liver elastography was performed to assess elasticity and extent of hepatic fibrosis. The change in LSM from Baseline to each visit was averaged among all participants in expressed in kilopascals (kPa). Positive changes in LSM values corresponded to an increase in stiffness and hepatic fibrosis. Liver Substudy Population: All participants who consented to participate in the liver elasticity substudy. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Week 48; FU Week 24 (up to 72 weeks overall)
Reported as:
Mean · kPa
Change From Baseline in Liver Stiffness Measure (LSM) in Groups A, B, C
kPaGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced FibrosisGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Week 48-0.49 ± 2.1510.376 ± 2.719-1.517 ± 1.685
FU Week 24-1.026 ± 2.269-0.72 ± 2.633-1.7 ± 1.033
SecondaryPercentage of Participants With >15% Drop in Height Percentile for Age in Group C

The percentage of participants with \>15% drop in weight percentile for age from Baseline to each visit was reported. Safety Population.

Time frame:
Weeks 30, 36; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With >15% Drop in Height Percentile for Age in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Week 3020
Week 3610
FU Week 410
FU Week 1210
FU Week 2420
SecondaryChange From Baseline in Height for Age Z-Score in Groups A and B

The difference between the population mean and raw scores was calculated as the height for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Baseline; Weeks 12, 24, 36, 48; FU Weeks 12, 24 (up to 72 weeks overall)
Reported as:
Mean · standard deviations
Change From Baseline in Height for Age Z-Score in Groups A and B
standard deviationsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Baseline0.271 ± 1.149-0.062 ± 1.17
Week 120.011 ± 0.258-0.006 ± 0.185
Week 24-0.04 ± 0.293-0.071 ± 0.264
Week 36-0.056 ± 0.337-0.025 ± 0.328
Week 48-0.099 ± 0.365-0.013 ± 0.284
FU Week 12-0.112 ± 0.404-0.037 ± 0.243
FU Week 24-0.117 ± 0.429-0.079 ± 0.282
SecondaryChange From Baseline in Weight for Age Z-Score in Groups A and B

The difference between the population mean and raw scores was calculated as the weight for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations.Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Mean · standard deviations
Change From Baseline in Weight for Age Z-Score in Groups A and B
standard deviationsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Baseline0.106 ± 1.154-0.047 ± 1.154
Week 1-0.024 ± 0.089—
Week 2-0.023 ± 0.108—
Week 4-0.048 ± 0.158—
Week 8-0.082 ± 0.228—
Week 12-0.09 ± 0.267-0.04 ± 0.241
Week 18-0.155 ± 0.309—
Week 24-0.165 ± 0.35-0.09 ± 0.323
Week 30-0.189 ± 0.372—
Week 36-0.192 ± 0.395-0.057 ± 0.338
Week 42-0.24 ± 0.375—
Week 48-0.214 ± 0.371-0.082 ± 0.343
FU Week 4-0.156 ± 0.346—
FU Week 12-0.089 ± 0.384-0.263 ± 0.333
FU Week 24-0.046 ± 0.452-0.322 ± 0.325
SecondaryChange From Baseline in Height for Age Z-Score in Group C

The difference between the population mean and raw scores was calculated as the height for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population.

Time frame:
Baseline; Weeks 12, 24, 36, 48; FU Weeks 12, 24 (up to 72 weeks overall)
Reported as:
Mean · standard deviations
Change From Baseline in Height for Age Z-Score in Group C
standard deviationsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Baseline0.586 ± 0.947
Week 120.07 ± 0.492
Week 240.262 ± 0.42
Week 360.3 ± 0.601
Week 480.19 ± 0.683
FU Week 120.205 ± 0.611
FU Week 240.064 ± 0.634
SecondaryChange From Baseline in Weight for Age Z-Score in Group C

The difference between the population mean and raw scores was calculated as the weight for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Mean · standard deviations
Change From Baseline in Weight for Age Z-Score in Group C
standard deviationsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Baseline0.187 ± 1.141
Week 1-0.044 ± 0.052
Week 2-0.023 ± 0.107
Week 40.049 ± 0.243
Week 8-0.041 ± 0.198
Week 120.012 ± 0.288
Week 18-0.018 ± 0.377
Week 24-0.089 ± 0.245
Week 30-0.094 ± 0.34
Week 360 ± 0.443
Week 42-0.032 ± 0.344
Week 48-0.208 ± 0.374
FU Week 4-0.054 ± 0.35
FU Week 12-0.156 ± 0.29
FU Week 24-0.161 ± 0.309
SecondaryPercentage of Participants With HBeAg Seroconversion at 24 Weeks After EOT in Group C

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Seroconversion at 24 Weeks After EOT in Group C
percentage of participantsGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Percentage of Participants With HBeAg Seroconversion at 24 Weeks After EOT in Group C30 ± 6.67
SecondaryChange From Baseline in Quantitative Serum ALT Level in Groups A and B

The change in quantitative ALT from Baseline to each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Mean · factor of ULN
Change From Baseline in Quantitative Serum ALT Level in Groups A and B
factor of ULNGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Week 10.606 ± 1.565—
Week 20.06 ± 2.283—
Week 40.564 ± 3.026—
Week 80.463 ± 3.225—
Week 120.415 ± 3.7320.598 ± 5.934
Week 180.288 ± 3.332—
Week 240.004 ± 3.496-0.462 ± 2.311
Week 30-0.1 ± 3.163—
Week 36-0.302 ± 2.8-0.51 ± 1.835
Week 42-0.436 ± 2.732—
Week 48-0.63 ± 2.652-0.939 ± 1.914
FU Week 4-1.474 ± 2.889—
FU Week 12-0.736 ± 2.972—
FU Week 24-1.302 ± 2.766-0.701 ± 2.22
SecondaryChange From Baseline in Quantitative HBeAg Level in Groups A and B

The change in quantitative HBeAg from Baseline to each visit was averaged among all participants and expressed in log10 PEIU/mL. ITT Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Reported as:
Mean · log10 PEIU/mL
Change From Baseline in Quantitative HBeAg Level in Groups A and B
log10 PEIU/mLGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Week 12-0.583 ± 0.672-0.225 ± 0.497
Week 24-0.834 ± 0.805-0.261 ± 0.612
Week 361.123 ± 0.91-0.3 ± 0.621
Week 48-1.28 ± 1.043-0.491 ± 0.74
FU Week 24-1.24 ± 1.205-0.452 ± 0.793
SecondaryChange From Baseline in Quantitative HBsAg Level in Groups A and B

The change in quantitative HBsAg from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Reported as:
Mean · log10 IU/mL
Change From Baseline in Quantitative HBsAg Level in Groups A and B
log10 IU/mLGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Week 12-0.444 ± 1.021-0.081 ± 0.356
Week 24-0.798 ± 1.343-0.032 ± 0.392
Week 36-1.051 ± 1.534-0.126 ± 0.26
Week 48-1.239 ± 1.652-0.188 ± 0.285
FU Week 24-0.936 ± 1.491-0.204 ± 0.316
SecondaryChange From Baseline in Quantitative Serum ALT Level in Group C

The change in quantitative ALT from Baseline to each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Reported as:
Mean · factor of ULN
Change From Baseline in Quantitative Serum ALT Level in Group C
factor of ULNGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Week 10.313 ± 0.414
Week 20.091 ± 0.991
Week 4-0.361 ± 1.566
Week 8-0.101 ± 1.895
Week 12-0.012 ± 1.613
Week 18-0.589 ± 0.996
Week 24-0.917 ± 1.31
Week 30-0.584 ± 1.73
Week 36-0.633 ± 1.455
Week 42-1.211 ± 1.05
Week 48-1.104 ± 1.084
FU Week 4-1.669 ± 0.95
FU Week 12-1.283 ± 1.501
FU Week 24-1.256 ± 1.757
SecondaryChange From Baseline in Quantitative HBeAg Level in Group C

The change in quantitative HBeAg from Baseline to each visit was averaged among all participants and expressed in log10 PEIU/mL. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.

Time frame:
Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Reported as:
Mean · log10 PEIU/mL
Change From Baseline in Quantitative HBeAg Level in Group C
log10 PEIU/mLGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Week 12-0.779 ± 0.645
Week 24-0.817 ± 0.678
Week 36-0.817 ± 0.685
Week 48-0.762 ± 0.818
FU Week 24-0.742 ± 0.84
SecondaryChange From Baseline in Quantitative HBsAg Level in Group C

The change in quantitative HBsAg from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population.

Time frame:
Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Reported as:
Mean · log10 IU/mL
Change From Baseline in Quantitative HBsAg Level in Group C
log10 IU/mLGroup C: PEG-IFN Monotherapy With Advanced Fibrosis
Week 12-0.397 ± 0.428
Week 24-0.71 ± 0.712
Week 36-0.943 ± 0.913
Week 48-1.01 ± 1.019
FU Week 24-1.088 ± 1.141
SecondaryPercentage of Participants With HBeAg Seroconversion Over Time in Groups A and B

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
Baseline, FU Years: 1, 2, 3, 4, 5
Reported as:
Number · percentage of subjects
Percentage of Participants With HBeAg Seroconversion Over Time in Groups A and B
percentage of subjectsGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced Fibrosis
Baseline0.00 ± 0.000.00 ± 0.00
Fu Year 132.7 ± 23.676.08 ± 1.25
Fu Year 233.7 ± 24.566.08 ± 1.25
Fu Year 346.5 ± 36.556.08 ± 1.25
Fu Year 430.7 ± 21.908.00 ± 2.22
Fu Year 55.9 ± 2.210.00 ± 0.00
SecondaryPercentage of Participants With Loss of HBeAg at 24 Weeks After the End of Switch Treatment Period: Switch Group

The percentage of participants with loss of HBeAg at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Loss of HBeAg at 24 Weeks After the End of Switch Treatment Period: Switch Group
percentage of participantsGroup D: Switch to PEG-IFN Monotherapy
Percentage of Participants With Loss of HBeAg at 24 Weeks After the End of Switch Treatment Period: Switch Group30.3 (15.59 to 48.71)
SecondaryPercentage of Participants With HBsAg Seroconversion at 24 Weeks After the End of Switch Treatment Period: Switch Group

HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at 24 Weeks After the End of Switch Treatment Period: Switch Group
percentage of participantsGroup D: Switch to PEG-IFN Monotherapy
Percentage of Participants With HBsAg Seroconversion at 24 Weeks After the End of Switch Treatment Period: Switch Group9.1 (1.92 to 24.33)
SecondaryPercentage of Participants With Loss of HBsAg at 24 Weeks After the End of Switch Treatment Period: Switch Group

HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Loss of HBsAg at 24 Weeks After the End of Switch Treatment Period: Switch Group
percentage of participantsGroup D: Switch to PEG-IFN Monotherapy
Percentage of Participants With Loss of HBsAg at 24 Weeks After the End of Switch Treatment Period: Switch Group12.1 (3.40 to 28.20)
SecondaryPercentage of Participants With Normal ALT at 24 Weeks After the End of Switch Treatment Period: Switch Group

Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at 24 Weeks After the End of Switch Treatment Period: Switch Group
percentage of participantsGroup D: Switch to PEG-IFN Monotherapy
Percentage of Participants With Normal ALT at 24 Weeks After the End of Switch Treatment Period: Switch Group42.4 (25.48 to 60.78)
SecondaryPercentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After the End of Switch Treatment Period: Switch Group

HBV DNA was quantified using polymerase chain reaction (PCR) by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After the End of Switch Treatment Period: Switch Group
percentage of participantsGroup D: Switch to PEG-IFN Monotherapy
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After the End of Switch Treatment Period: Switch Group36.4 (20.40 to 54.88)
SecondaryPercentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group

HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group
percentage of participantsGroup D: Switch to PEG-IFN Monotherapy
Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group27.3 (13.30 to 45.52)
SecondaryPercentage of Participants With HBV DNA Undetectable at 24 Weeks After the End of Switch Treatment Period: Switch Group

HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA Undetectable at 24 Weeks After the End of Switch Treatment Period: Switch Group
percentage of participantsGroup D: Switch to PEG-IFN Monotherapy
Percentage of Participants With HBV DNA Undetectable at 24 Weeks After the End of Switch Treatment Period: Switch Group18.2 (6.98 to 35.46)
SecondaryPercentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group
percentage of participantsGroup D: Switch to PEG-IFN Monotherapy
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group27.3 (13.30 to 45.52)
SecondaryPercentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group

HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.

Time frame:
FU Week 24 (up to 72 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group
percentage of participantsGroup D: Switch to PEG-IFN Monotherapy
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group21.2 (8.98 to 38.91)

Adverse events

Collected over From Baseline to approximately 4.5 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: PEG-IFN Monotherapy Without Advanced Fibrosis0/101 (0%)6/101 (5.9%)80/101 (79.2%)
Group B: Untreated Control Without Advanced Fibrosis0/49 (0%)1/49 (2%)18/49 (36.7%)
Group C: PEG-IFN Monotherapy With Advanced Fibrosis0/10 (0%)0/10 (0%)9/10 (90%)
Group D: Switch to PEG-IFN Monotherapy0/33 (0%)2/33 (6.1%)21/33 (63.6%)
Group A - Long Term Follow-up0/101 (0%)0/101 (0%)25/101 (24.8%)
Group B - Long Term Follow-up0/49 (0%)0/49 (0%)6/49 (12.2%)
Group C Long Term Follow-up0/10 (0%)0/10 (0%)0/10 (0%)
Group D - Long Term Follow-up0/33 (0%)0/33 (0%)27/33 (81.8%)
Most frequent serious events
Most frequent serious events
EventGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced FibrosisGroup C: PEG-IFN Monotherapy With Advanced FibrosisGroup D: Switch to PEG-IFN MonotherapyGroup A - Long Term Follow-upGroup B - Long Term Follow-upGroup C Long Term Follow-upGroup D - Long Term Follow-up
NephropathyRenal and urinary disorders0/1010/490/101/330/1010/490/100/33
PneumoniaInfections and infestations0/1010/490/101/330/1010/490/100/33
Suicidal ideationPsychiatric disorders0/1011/490/100/330/1010/490/100/33
Alanine aminotransferase increasedInvestigations1/1010/490/100/330/1010/490/100/33
Aspartate aminotransferase increasedInvestigations1/1010/490/100/330/1010/490/100/33
OsteochondrosisMusculoskeletal and connective tissue disorders1/1010/490/100/330/1010/490/100/33
Hepatitis BInfections and infestations1/1010/490/100/330/1010/490/100/33
Latent tuberculosisInfections and infestations1/1010/490/100/330/1010/490/100/33
Microsporum infectionInfections and infestations1/1010/490/100/330/1010/490/100/33
TonsillitisInfections and infestations1/1010/490/100/330/1010/490/100/33
Most frequent other events
Showing 10 of 85
Most frequent other events
EventGroup A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced FibrosisGroup C: PEG-IFN Monotherapy With Advanced FibrosisGroup D: Switch to PEG-IFN MonotherapyGroup A - Long Term Follow-upGroup B - Long Term Follow-upGroup C Long Term Follow-upGroup D - Long Term Follow-up
PyrexiaGeneral disorders49/1015/498/1017/331/1010/490/100/33
HeadacheNervous system disorders30/1012/494/1011/331/1010/490/1017/33
AstheniaGeneral disorders10/1010/490/104/330/1010/490/1010/33
CoughRespiratory, thoracic and mediastinal disorders14/1013/493/101/332/1010/490/100/33
NauseaGastrointestinal disorders7/1010/493/101/330/1010/490/102/33
VomitingGastrointestinal disorders14/1010/493/102/330/1010/490/102/33
Alanine aminotransferase increasedInvestigations9/1014/491/102/333/1010/490/107/33
EpistaxisRespiratory, thoracic and mediastinal disorders8/1010/492/102/330/1010/490/102/33
Abdominal painGastrointestinal disorders19/1010/490/104/330/1010/490/102/33
MyalgiaMusculoskeletal and connective tissue disorders0/1010/490/100/330/1010/490/106/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced FibrosisGroup C: PEG-IFN Monotherapy With Advanced FibrosisTotal
Mean10.41 ± 4.5711.2 ± 5.016.7 ± 3.2710.55 ± 4.81
Age, Customized
Age, Customized(Participants)Group A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced FibrosisGroup C: PEG-IFN Monotherapy With Advanced FibrosisTotal
In utero0000
Preterm newborn infants (gestational age < 37 wks)0000
Newborns (0-27 days)0000
Infants and toddlers (28 days-23 months)0000
Children (2-11 years)5320982
Adolescents (12-17 years)4830179
Adults (18-64 years)0000
From 65-84 years0000
85 years and over0000
Sex: Female, Male
Sex: Female, Male(Participants)Group A: PEG-IFN Monotherapy Without Advanced FibrosisGroup B: Untreated Control Without Advanced FibrosisGroup C: PEG-IFN Monotherapy With Advanced FibrosisTotal
Female3718257
Male64328104
08

Study locations

39 sites
  • Univ of California SF, Benioff Children's Hospital; Pediatrics, Gastro, Hepatology & Nutrition
    San Francisco, California 94143, United States
  • Johns Hopkins Hospital - Pediatric Gastroenterology
    Baltimore, Maryland 21287-5554, United States
  • Children's Hospital Boston-Harvard Medical School; Division of Gastoenterology
    Boston, Massachusetts 02115, United States
  • St. Louis University - Cardinal Glennon Children's Medical Center
    Saint Louis, Missouri 63104, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Womens and Childrens Hospital; Department of Gastroenterology
    North Adelaide, South Australia 5006, Australia
  • Royal Children's Hospital; Department of Gastroenterology
    Melbourne, Victoria 3053, Australia
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • Specialized Hospital for Active Treatment of Pediatrics Diseases; Clinic of Gastroenterology
    Sofia, 1612, Bulgaria
  • University Hospital "St. Marine"; Dept. of Pediatrics
    Varna, 9000, Bulgaria
  • Beijing You An Hospital; Digestive Dept
    Beijing City, 100069, China
  • Beijing 302 Hospital; No. 2 Infectious Disease Section
    Beijing, 100039, China
  • the First Hospital of Jilin University
    Changchun, 130021, China
  • Southwest Hospital , Third Military Medical University
    Chongqing, 400038, China
  • The Eighth People's Hospital of Guangzhou
    Guangzhou, 510060, China
  • The Third Affiliated Hospital of Sun Yat-Sen University
    Guangzhou, 510630, China
  • The First Affilliated Hospital of Kunming Medical College
    Kunming, 650032, China
  • Xinjiang Uygur Autonomous Region Hospital of Chinese Traditional Medicine
    Urumqi (乌鲁木齐), 830000, China
  • Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
    Wuhan, 430030, China
  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
    Xi'an, 710061, China
  • HELIOS Klinikum Wuppertal, Zentrum für Kinder- und Jugendmedizin, Universität Witten-Herdecke
    Wuppertal, 42283, Germany
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Hadassah University Hospital - Ein Kerem
    Jerusalem, 9112001, Israel
  • Western Galilee Hospital - Nahariya
    Nahariya, 22100, Israel
  • Uni Degli Studi Di Bologna - Policlinica S. Orsola; Inst. Di Malattie Infettive
    Bologna, Emilia-Romagna 40138, Italy
  • Wojewodzki Szpital Obserwacyjno-Zakazny; Oddział Pediatrii, Chorób Infekcyjnych i Hepatologii
    Bydgoszcz, 85-030, Poland
  • Krakowski Szpital Specjalistyczny im Jana Pawła II; Oddział Chorób Infekcyjnych Dzieci
    Krakow, 31-202, Poland
  • Wojewodzki Specjalistyczny Szpital im. Dr W.Bieganskiego; Oddział Obserwacyjno-Zakażny dla Dzieci
    Łodz, 91-347, Poland
  • SFI Sceintific Research institute of nutrition of RAMS
    Moscow, 115446, Russian Federation
  • SI Sceintific children health center RAMS
    Moscow, 119991, Russian Federation
  • FSI Scientific research Institute of children's infections
    Saint Petersburg, 197022, Russian Federation
  • MC Gepatolog
    Samara, 443100, Russian Federation
  • Kyiv Children's Clinical Infectious Diseases Hospital
    Kyiv, 01119, Ukraine
  • SI Institute of the pediatrics, obstetrics and gynecology
    Kyiv, 04050, Ukraine
  • Birmingham Children'S Hopsital; Liver Unit
    Birmingham, B4 6NH, United Kingdom
  • Kings College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
  • Imperial College Healthcare Trust
    London, W2 1PG, United Kingdom
09

References and documents

Publications

  • Wirth S, Zhang H, Hardikar W, Schwarz KB, Sokal E, Yang W, Fan H, Morozov V, Mao Q, Deng H, Huang Y, Yang L, Frey N, Nasmyth-Miller C, Pavlovic V, Wat C. Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study. Hepatology. 2018 Nov;68(5):1681-1694. doi: 10.1002/hep.30050. Epub 2018 Oct 8. PubMed 29689122 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in Jul 2015, 35 months.

Results were first posted in Aug 2016, 1 year 1 month after primary completion.

Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2011
First posted
Jan 27, 2012
StartActual
Jul 11, 2012
Primary completionActual
Jul 9, 2015
CompletionActual
Oct 18, 2021
Results first posted
Aug 17, 2016
Last update
Nov 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01519960
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 27, 2012
Start date
Jul 11, 2012
Primary completion
Jul 9, 2015
Completion
Oct 18, 2021
Results posted
Aug 17, 2016
Last update
Nov 18, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion